NicVAX vaccine

BIOLOGICAL6 trials

Sponsors

Nabi Biopharmaceuticals, Maastricht University Medical Center

Conditions

Nicotine DependenceSmokingSmoking BehaviorSmoking CessationSmoking Lapse BehaviorSmoking Relapse BehaviorTobacco Cessation

Phase 2

Efficacy and Safety of NicVAX® Co-administered With Varenicline (Champix®)

CompletedNCT00995033

Maastricht University Medical CenterSmoking Behavior, Smoking Lapse Behavior, Smoking Relapse Behavior

Start: 2009-10-31End: 2012-09-30Updated: 2013-02-20

Phase 3

NicVAX/Placebo as an Aid for Smoking Cessation

CompletedNCT00836199

Nabi BiopharmaceuticalsSmoking, Smoking Cessation, Tobacco Cessation

Start: 2009-10-31End: 2011-07-31Updated: 2012-05-09

A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation

CompletedNCT01102114

Nabi BiopharmaceuticalsSmoking Cessation

Start: 2010-03-31End: 2011-11-30Updated: 2012-05-09

Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies

CompletedNCT01178346

Nabi BiopharmaceuticalsSmoking Cessation

Start: 2010-07-31End: 2011-11-30Updated: 2012-05-09

A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers

CompletedNCT01375933

Nabi BiopharmaceuticalsSmoking

Start: 2011-05-31End: 2011-10-31Updated: 2012-05-14

Unknown Phase

A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation

CompletedNCT01304810

Nabi BiopharmaceuticalsNicotine Dependence, Smoking Cessation

Start: 2011-01-31End: 2011-08-31Updated: 2012-05-14

Related Papers

The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial.

2012-12-0620 citations